Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.
Journal: American journal of respiratory and critical care medicine
Published: June 02, 2025
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective.
Journal: The Lancet. Respiratory medicine
Published: May 17, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: May 08, 2023
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Journal: The Lancet. Respiratory medicine
Published: October 05, 2022
Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: October 21, 2021
Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial.
Journal: Thorax
Published: June 11, 2021
A new path for CF clinical trials through the use of historical controls.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: January 20, 2021
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.
Journal: Annals of the American Thoracic Society
Published: January 19, 2021
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: October 28, 2020
Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis.
Journal: The European respiratory journal
Published: September 03, 2020
Building global development strategies for cf therapeutics during a transitional cftr modulator era.
Building global development strategies for cf therapeutics during a transitional cftr modulator era.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 07, 2020
Last Updated: 09/26/2026